Arzneiwerk AG VIDA (FRA:TLIK) ROCE %: -0.92% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TLIK Arzneiwerk AG VIDA FRA:TLIK
40 GF Score
Price €0.21
! 7 Warning Signs
View Full Analysis

What is Arzneiwerk AG VIDA ROCE %?

Arzneiwerk AG VIDA FRA:TLIK +0.98% 40 ROCE % is -0.92% as of Mar. 2026. GuruFocus rates FRA:TLIK with a GF Score™ of 40/100. The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Arzneiwerk AG VIDA's annualized ROCE % for the quarter that ended in Mar. 2026 was -0.92%.

Arzneiwerk AG VIDA  (FRA:TLIK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Arzneiwerk AG VIDA ROCE % Related Terms

Arzneiwerk AG VIDA ROCE % Historical Data

* Premium members only.

The historical data trend for Arzneiwerk AG VIDA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arzneiwerk AG VIDA ROCE % Chart

Arzneiwerk AG VIDA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.92 -114.36 -204.19 -84.85 -43.52

Arzneiwerk AG VIDA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.21 -39.26 -13.57 19.11 -0.92
FRA:TLIK
40GF Score
Arzneiwerk AG VIDA FRA:TLIK
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arzneiwerk AG VIDA ROCE % Calculation

Arzneiwerk AG VIDA's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-0.366/( ( (4.168 - 3.221) + (4.516 - 3.781) )/ 2 )
=-0.366/( (0.947+0.735)/ 2 )
=-0.366/0.841
=-43.52 %

Arzneiwerk AG VIDA's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-0.012/( ( (4.516 - 3.781) + (4.568 - 2.706) )/ 2 )
=-0.012/( ( 0.735 + 1.862 )/ 2 )
=-0.012/1.2985
=-0.92 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -0.92% mean?
Arzneiwerk AG VIDA (FRA:TLIK) has a ROCE % of -0.92% as of Mar. 2026.
Is Arzneiwerk AG VIDA's ROCE % too high?
Arzneiwerk AG VIDA's current ROCE % is -0.92%. Overall, Arzneiwerk AG VIDA has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Arzneiwerk AG VIDA's ROCE % compare to MCK and COR?
Arzneiwerk AG VIDA's ROCE % of -0.92% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 9.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 9.15, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 9.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arzneiwerk AG VIDA's current ROCE % is -0.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arzneiwerk AG VIDA stock overvalued right now?
Arzneiwerk AG VIDA (FRA:TLIK) has a current ROCE % of -0.92%. The current ROCE % is -0.92%. Arzneiwerk AG VIDA's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Arzneiwerk AG VIDA (FRA:TLIK), the current ROCE % is -0.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arzneiwerk AG VIDA Business Description

Other Exchanges TLIK:Germany
Address Ordensmeisterstrasse 15-16, Berlin, DEU, 12099
Arzneiwerk AG VIDA is active in the pharmaceutical industry. The Pharma segment combines pharmaceutical supply with a focus on digitalization and process optimization along the pharmaceutical value chains and the management of large data volumes in the pharmaceutical industry. The company focuses on the growth area of specialty pharma in Germany and Europe.
40GF Score

Get the complete analysis for FRA:TLIK

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.21
Price